Patents by Inventor Lingzhi Xiao

Lingzhi Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
    Publication number: 20220372513
    Abstract: Viral vectors, lentiviral particles, and modified cells are disclosed. They encode or express a small RNA capable of targeting the KIF11 gene. In embodiments, the viral vectors and lentiviral particles further comprise and a KIF11 gene whose non-coding region has been modified such that it is resistant to activity by the small RNA.
    Type: Application
    Filed: March 22, 2022
    Publication date: November 24, 2022
    Inventors: Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
  • COMBINATION VECTORS AND METHODS FOR TREATING CANCER
    Publication number: 20220251563
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Application
    Filed: January 6, 2022
    Publication date: August 11, 2022
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • Vector system for expressing regulatory RNA
    Patent number: 11352646
    Abstract: Viral vectors, lentiviral particles, and modified cells are disclosed. They encode or express a small RNA capable of targeting the KIF11 gene. In embodiments, the viral vectors and lenti viral particles further comprise and a KIF11 gene whose non-coding region has been modified such that it is resistant to activity by the small RNA.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: June 7, 2022
    Assignee: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
  • OPTIMIZED PHENYLANANINE HYDROXYLASE EXPRESSION
    Publication number: 20220162643
    Abstract: A lentiviral vector system for expressing a lentiviral particle is disclosed. The lentiviral vector system includes a therapeutic vector. The lentiviral vector system produces a lentiviral particle that encodes a codon-optimized PAH for upregulating PAH expression in the cells of a subject afflicted with phenylketonuria (PKU).
    Type: Application
    Filed: June 1, 2020
    Publication date: May 26, 2022
    Applicant: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
  • Combination vectors and methods for treating cancer
    Patent number: 11242527
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: February 8, 2022
    Assignee: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
    Publication number: 20210403949
    Abstract: Viral vectors, lentiviral particles, and modified cells are disclosed. They encode or express a small RNA capable of targeting the KIF11 gene. In embodiments, the viral vectors and lenti viral particles further comprise and a KIF11 gene whose non-coding region has been modified such that it is resistant to activity by the small RNA.
    Type: Application
    Filed: November 5, 2019
    Publication date: December 30, 2021
    Applicant: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
  • Combination vectors and methods for treating cancer
    Patent number: 10975374
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: April 13, 2021
    Assignee: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • COMBINATION VECTORS AND METHODS FOR TREATING CANCER
    Publication number: 20210047644
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 18, 2021
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • HIV IMMUNOTHERAPY WITH NO PRE-IMMUNIZATION STEP
    Publication number: 20200384021
    Abstract: The present invention relates generally to immunotherapy for the treatment or prevention of HIV. In particular, the disclosure provides lentiviral vectors and associated methods that are optimized to treat HIV without a pre-immunization step.
    Type: Application
    Filed: January 9, 2018
    Publication date: December 10, 2020
    Inventors: Haishan Li, Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
  • Combination vectors and methods for treating cancer
    Patent number: 10767183
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 8, 2020
    Assignee: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • METHODS AND COMPOSITIONS FOR THE ACTIVATION OF TUMOR CYTOTOXICITY VIA HUMAN GAMMA-DELTA T-CELLS
    Publication number: 20200181645
    Abstract: The present disclosure relates generally to methods and compositions for activating gamma-delta (GD) T cells. Such methods and compositions can be used to treat cancer.
    Type: Application
    Filed: June 15, 2018
    Publication date: June 11, 2020
    Inventors: Charles David Pauza, Tyler Lahusen, Haishan Li, Mei-Ling Liou, Lingzhi Xiao
  • COMBINATION VECTORS AND METHODS FOR TREATING CANCER
    Publication number: 20190078096
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Application
    Filed: March 9, 2017
    Publication date: March 14, 2019
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza